Florida Cancer Specialists & Research Institute Studies Featured at ASCO® Genitourinary Cancers Symposium

Fort Myers, Fla., Mar. 9, 2022 – Three Florida Cancer Specialists & Research Institute (FCS) physicians presented clinical research findings at the American Society of Clinical Oncology (ASCO®) 2022 Genitourinary Cancers Symposium held February 17 – 19 in San Francisco, CA.  Research conducted at FCS clinics throughout Florida were featured in the program, which focused on innovative new findings in the study, diagnosis and treatment of malignancies that occur in male and female reproductive organs.

Manish R. Patel, MD, Director of Drug Development, was lead author of a multi-site Phase 1/2 study on treatment of prostate cancer entitled “DS-7300 (B7-H3 DXd-ADC) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): a subgroup analysis of a phase 1/2 multicenter study” The analysis from this study evaluating a B7-H3 antibody drug conjugate was encouraging and warrants future investigations.

Lucio N. Gordan, MD, FCS Chief Medical Officer Therapeutics and Analytics, was first author of a presentation that examined major adverse cardiovascular risk following androgen deprivation therapy for the treatment of prostate cancer entitled “Comparison of major adverse cardiovascular events risk after androgen deprivation therapy initiation by body mass index.”

He also co-authored the study “Real-world analyses of major adverse cardiovascular event risk by drug class after initiation of androgen deprivation therapy” which was presented at the conference.

A fourth presentation at ASCO GU included a study co-authored by Ivor Percent, MD, FCS hematologist and medical oncologist and member of the FCS clinical research team, “Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC),” evaluating a first-in-class oral PROteolysis TArgetingChimera protein degrader on patients who have limited treatment options.

“Prostate cancer is the most common cancer in American men, with more than 183,000 new cases diagnosed each year,” said FCS President & Managing Physician Michael Diaz, MD. “FCS is at the forefront of scientific discoveries that are improving outcomes for prostate cancer patients.”

The American Society of Clinical Oncology, Inc. (ASCO®) represents nearly 45,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of high quality and equitable patient care, ASCO works to conquer cancer.

###

For More Information, Contact:
Jen Bradley, Director Corporate Communications
Jennifer.Bradley@FLCancer.com
847.280.1740